J Xu1,2, C Ni2, C Ma1, L Zhang1, X Jing1, C Li1, Y Liu3, X Qu4. 1. Institute of Basic Medical Sciences, Qilu Hospital of Shandong University, #107 West Wenhua Road, Jinan, 250012, Shandong, People's Republic of China. 2. Department of Medical Oncology, Tai'an City Central Hospital, Tai'an, 271000, Shandong, People's Republic of China. 3. Department of Medical Oncology, Qilu Hospital of Shandong University, #107 West Wenhua Road, Jinan, 250012, Shandong, People's Republic of China. y.g.liu@163.com. 4. Institute of Basic Medical Sciences, Qilu Hospital of Shandong University, #107 West Wenhua Road, Jinan, 250012, Shandong, People's Republic of China. quxun@sdu.edu.cn.
Abstract
PURPOSE: Proinflammatory markers, including neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR), are associated with many aspects of different malignancies. The aim of this study was to assess the associations of NLR and PLR with estrogen receptor (ER) and progesterone receptor (PR) expression in locally advanced breast cancer patients and their changes after neoadjuvant chemotherapy (NAC). Whether these parameters were predictive for the response to NAC in breast cancer patients was also evaluated. METHODS: 132 Female primary locally advanced breast cancer patients treated with either ET (epirubicin-docetaxel), TEC (docetaxel-epirubicin-cyclophosphamide), or CEF (cyclophosphamide-epirubicin-fluorouracil) as NAC were retrospectively studied. NLR and PLR were calculated from peripheral blood cell count and their optimal cutoff levels were determined by receiver operating characteristic curves. RESULTS: The proportion of ER-positive breast cancers before NAC was higher both in NLRlow (<2.05) group and PLRlow group (<159.01). Changes in ER or PR expression level or status were observed in some patients. The alterations of NLR and PLR after NAC correlated with chemotherapy regimens, and elevated PLR was found. The patients with low pretreatment NLR (<1.67) or PLR (<151.27) had better responses to NAC than those with high NLR (≥1.67, 67.3 vs. 47.1%, P < 0.05) or PLR (≥151.27, 64.0 vs. 45.1%, P < 0.05). CONCLUSIONS: The patients with low pretreatment NLR (<2.05) or PLR (<159.01) had higher ER expression. Changes in ER and PR expression status or level occured following NAC. Elevated PLR was found aft-NAC. Pretreatment NLR and PLR may be important predictive indicators for NAC response in breast cancer patients.
PURPOSE: Proinflammatory markers, including neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR), are associated with many aspects of different malignancies. The aim of this study was to assess the associations of NLR and PLR with estrogen receptor (ER) and progesterone receptor (PR) expression in locally advanced breast cancerpatients and their changes after neoadjuvant chemotherapy (NAC). Whether these parameters were predictive for the response to NAC in breast cancerpatients was also evaluated. METHODS: 132 Female primary locally advanced breast cancerpatients treated with either ET (epirubicin-docetaxel), TEC (docetaxel-epirubicin-cyclophosphamide), or CEF (cyclophosphamide-epirubicin-fluorouracil) as NAC were retrospectively studied. NLR and PLR were calculated from peripheral blood cell count and their optimal cutoff levels were determined by receiver operating characteristic curves. RESULTS: The proportion of ER-positive breast cancers before NAC was higher both in NLRlow (<2.05) group and PLRlow group (<159.01). Changes in ER or PR expression level or status were observed in some patients. The alterations of NLR and PLR after NAC correlated with chemotherapy regimens, and elevated PLR was found. The patients with low pretreatment NLR (<1.67) or PLR (<151.27) had better responses to NAC than those with high NLR (≥1.67, 67.3 vs. 47.1%, P < 0.05) or PLR (≥151.27, 64.0 vs. 45.1%, P < 0.05). CONCLUSIONS: The patients with low pretreatment NLR (<2.05) or PLR (<159.01) had higher ER expression. Changes in ER and PR expression status or level occured following NAC. Elevated PLR was found aft-NAC. Pretreatment NLR and PLR may be important predictive indicators for NAC response in breast cancerpatients.
Authors: Marcin Sinacki; Andrzej Badzio; Marzena Wełnicka-Jaśkiewicz; Jan Bogaerts; Martine J Piccart; Patrick Therasse; Ian E Smith; Thomas Hatschek; Jacek Jassem Journal: Breast Date: 2010-09-25 Impact factor: 4.380
Authors: Melek Karakurt Eryilmaz; Hasan Mutlu; Derya Kivrak Salim; Fatma Yalcin Musri; Deniz Tural; Hasan Senol Coskun Journal: Asian Pac J Cancer Prev Date: 2014
Authors: Christoph Suppan; Vesna Bjelic-Radisic; Marlen La Garde; Andrea Groselj-Strele; Katharina Eberhard; Hellmut Samonigg; Hans Loibner; Nadia Dandachi; Marija Balic Journal: BMC Cancer Date: 2015-12-29 Impact factor: 4.430
Authors: Javier Cuello-López; Ana Fidalgo-Zapata; Laura López-Agudelo; Elsa Vásquez-Trespalacios Journal: PLoS One Date: 2018-11-14 Impact factor: 3.240
Authors: Kwan Ho Lee; Eun Young Kim; Ji Sup Yun; Yong Lai Park; Sung-Im Do; Seoung Wan Chae; Chan Heun Park Journal: BMC Cancer Date: 2018-10-01 Impact factor: 4.430
Authors: Ling Bo Xue; Yong Hong Liu; Bo Zhang; Yan Fang Yang; Dong Yang; Li Wei Zhang; Jian Jin; Jie Li Journal: Medicine (Baltimore) Date: 2019-01 Impact factor: 1.889